In this paper, a new supervised clustering and classification method is proposed. First, the application of discriminant partial least squares (DPLS) for the selection of a minimum number of key genes is applied on a gene expression microarray data set. Second, supervised hierarchical clustering based on the information of the cancer type is subsequently proposed to find key gene groups and to group the cancer samples into different subclasses. Here, the weights of the genes in the DPLS are proportional to their importance in the determination of the class labels, that is, the variable importance in the projection (VIP) information of the DPLS method. The power of the gene selection method and the proposed supervised hierarchical clustering method is illustrated on a three microarray data sets of leukemia, breast, and colon cancer. Supervised machine learning algorithms thus enable the subtype classification 3 data sets solely on the basis of molecular-level monitoring. Compared to unsupervised clustering, the supervised method performed better for discriminating between cancer types and cancer subtypes for the leukemia data set. The performance of the proposed method, using only a limited set of informative genes, is demonstrated to be comparable or better than results reported in the literature for the three data sets. Furthermore the method was successful in predicting the outcome of medical treatment (success or failure) based on the microarray data, which could make the method an important tool for clinical doctors.
Introduction
The use of the relatively new DNA microarray technology, which enables simultaneous monitoring of the expression pattern of thousands of genes, has led to an explosion in the amount of readily available gene expression data. Correspondingly, there now is a great need for methods capable of interpreting, visualizing and analyzing the gene expression pattern data. However, analyzing gene expression data is far from straightforward (Lu and Han, 2003) . The data are typically characterized by a very high dimensionality (high number of genes), a relatively small number of samples (observations), irrelevant features, as well as collinear and multivariate characteristics. In particular, conventional statistical techniques do not work well (or even not at all) for analysis of gene expression data, when the number of variables (genes) by far exceeds the number of samples. Thus, there is great need for new methods that are capable of analyzing microarray data. The first step in creating such a new method consists of extracting the fundamental features (or genes) of the gene expression data set (i.e. a dimensionality reduction). The second step is the usage of the retained expression data within the desired framework of data analysis, which could for example be classifying similar genes or samples, and/or identifying the tumor class for a given sample .
A lot of studies have used microarray technology to analyze gene expression in colon, breast, leukemia and other cancers (Golub et al., 1999; Alizadeh et al., 2000; Furey et al., 2000; Quackenbush, 2001; Cho et al., 2002; Dudoit et al., 2002; Rocke, 2002a, 2002b; Stephanopoulos et al., 2002; Hampton and Frierson, 2003; Ishida et al., 2003; Lu and Han, 2003; Takahashi et al., 2003 Takahashi et al., , 2004 Takahashi et al., , 2005a Kulkarni et al., 2005; Bullinger et al., 2007) . These studies have demonstrated the ability of expression profiling to cluster similar genes and classify tumors. Lu and Han (2003) provide a detailed review on methodologies that are commonly used for microarray gene expression analysis.
Many machine learning methods using support vector machines (SVM) and Fisher's linear discriminant analysis (FLD) on gene expression profiles have recently been applied in cancer classification for colon and breast cancer, for leukemia and other tumors. Moler et al., 2000; Furey et al., 2000; Xiong et al., 2001; Zhang et al., 2001; Dudoit et al., 2002; Stephanopoulos et al., 2002) . These investigations have clearly shown the capability of gene expression profiling for classifying the tumors. Gene expression profiles may give more objective information than traditional morphological tumor characterization methods.
On the other hand, there are a number of research works about the methodologies to classify samples into subclasses by the selected genes and the methodology to select gene for such purpose. Bhattacharjee et al. (2001) suggested a hierarchical and probabilistic clustering of expression data defined distinct subclasses of lung adenocarcinoma. Two genes of neuroendocrine genes and of type II pneumocyte genes with high relative expression are selected for the tumor subclass. It was revealed a less favorable outcome for the adenocarcinomas with neuroendocrine gene expression. Tibshirani et al. (2002) suggested an approach to cancer class prediction from gene expression profiling, based on an enhancement of the simple nearest prototype classifier for subclass cancer. Ishida et al. (2003) suggested a new methodology for key gene selection and clinical result for the classification of synthetic retinoids and retinoid synergists. Fifty marker genes whose expression pattern could distinguish these classes are selected by analyzing the effects of all-trans retinoic acid and 9-cis retinoic acid on the gene expressions in a leukemia cell line. And then they found the existence of two subclasses among the selected genes. Bullinger et al. (2007) analyzed the AML patients with CBF leukemia using DNA microarray technology and correlated findings with known collaborating aberrations in CBF AML It leads to the identification of clinically relevant subclasses, highlighting genes and pathways of potential pathogenic relevance that provide a basis for novel molecular targeted therapeutic approaches.
In this paper, we first explain the gene selection method, discriminant partial least squares (DPLS), which was used for the selection of the key genes. Secondly, various supervised classification methods, such as principal component analysis (PCA), Fisher's linear discriminant (FLD) analysis and support vector machines (SVM) are subsequently used to classify the gene expression data sets. Third, a new supervised hierarchical clustering method then is proposed using information obtained from the DPLS. The results in microarray dataset shows that that the proposed method allows prediction of tumor type and subtype for three microarray data sets from leukemia, breast and colon cancer patients, as well as establishment of the relationship between expression-based subclass and clinical treatment outcome. Performance of the classification methods is compared with other results reported in the literature.
Material and Methods

Gene selection and dimension reduction in gene expression data
Gene selection (feature selection) is a fundamental issue in gene expression data based tumor clustering and classification. In our research we used discriminant partial least squares (DPLS) as selection method Rocke, 2002a, 2002b; Sun, 2004a Sun, , 2004b . In DPLS, X n m ∈ℜ * corresponds to a gene expression data and each column in Y n p ∈ℜ * corresponds to a class. Each element of Y is either 1 or 0. The DPLS method can be explained mathematically as follows: DPLS components are obtained in such a way that the sample covariance between the response variables (in this case the cancer subclasses) and a linear combination of the predictors (genes) are maximized. In other words, DPLS finds a weight vector w which satisfies (Yeung and Ruzzo, 2001; Cho et al., 2002; Rocke, 2002a, 2002b; Sun, 2004a Sun, , 2004b Yoo et al., 2005) : In the DPLS method, gene components are selected by sequentially maximizing the covariance between the cancer types and a linear combination of the genes (also subject to orthogonality and normality constraints). This procedure identifies the gene component weights, w, for which cov(Xw, y) reaches a maximum, where y is the response vector of cancer subtypes. Note that once the DPLS weight vectors are computed, relevant genes are selected via the variable importance in the projection (VIP), which is defined as follows (Eriksson et al., 1995) :
where w ak is the PLS weight for the gene expression profiles. The VIP is the sum over all model dimensions of the contributions and can be considered as a good measure of the influence of all genes in the model on the cancer class prediction. For a given DPLS dimension, VIP k is equal to the squared PLS weight (w ak ) 2 . The VIP can be considered as a measure of how much a certain gene corresponds to the samples. Thus, we can select important genes, that is genes that allow to discriminate between different cancer classes, based on the VIP value. This concept is similar to that underlying the selection of genes on the basis of the weights of a linear discriminant function, whereby the genes with the top K weights are selected (where K is the desired number of the selected genes). Therefore, given the DPLS model, a set of K high-ranking genes is obtained by selecting the genes with the top K VIP weights (Sun, 2004a (Sun, , 2004b Yoo et al., 2005) .
In spite of applying gene selection of the original data set, microarray data may still contain redundant information. In this paper, two methods of principal component analysis and Fisher's linear discriminant analysis are used for the dimension reduction after the gene selection. Principal component analysis (PCA) is a dimensionality reduction technique that uses a linear transformation to sequentially maximize the variance of a linear combination of the predictor variables (Nguyen and Rocke, 2002a) ,
subject to the orthogonality constraint
where S′ =X′X is the covariance matrix (Quackenbush, 2001) . A lot of research work using PCA and SVD has been performed for analyzing and classifying gene expression data (Alter et al., 2000; Yeung and Ruzzo, 2001; Landgrebe et al., 2002; Méndez et al., 2002 ). Fisher's linear discriminant analysis (FLD) is a linear dimensionality reduction technique that is optimal in terms of maximizing the separation amongst these classes. Where PCA seeks directions that are efficient for representation, FLD seeks directions that are efficient for discrimination. Hence, FLD determines a set of projection vectors which simultaneously maximize the scatter between classes and minimize the scatter within each class, and which maximize the separability of the data (Duda et al., 2001) . The projection vector of FLD can be obtained by solving the following optimization problem: where S B is the between-class scatter matrix,
T , x i is the mean vector for class i, and x is the total mean vector (Duda et al., 2001) . With FLD vectors determined, each sample can then be classified in this reduced FLD space using discrimination analysis. Several researches are used to create a linear projection of gene expression measurements that maximizes the separation of different sample classes and to develop the classification method which used a distance measure within a FLD space (Cho et al., 2002; Hwang et al., 2002; Stephanopoulos et al., 2002) .
Cancer classification by machine learning
The purpose of supervised gene expression data analysis is to construct well-performing classifiers using machine learning algorithms such as linear discriminants, decision trees or support vector machines, which assign predefined classes to a given expression profile (Alizadeh et al., 2000) . In this paper, two classification methods of linear discriminant function and support vector machine are used to classify the type of a cancer.
A linear discrimination function (LDF) that is a linear combination of the components of x can be written as
where w is the weight vector and b is the bias. Given the sets of the input vector to train the classifier, the training process involves the adjustment of the weight vector w in such a way that the two classes (w 1 and w 2 ) are linearly separable (Haykin, 1999; Duda et al., 2001) . On the other hand, support vector machines (SVM), which are a kind of supervised machine learning techniques, have been shown to perform well in multiple areas of biological analysis, including the evaluation of microarray gene expression data. While the linear discriminant analysis described above can produce linear decision boundaries for the classification, SVM produces nonlinear boundaries as a result of generating linear decision boundaries in the feature space (Vapnik, 1995; Hastie et al., 2001) . SVM has demonstrated the ability to not only correctly separate entities into appropriate classes, but also to identify instances whose established classification is not supported by the data (Brazma and Vilo, 2000; Furey et al., 2000; Shipp et al., 2002) .
Supervised Clustering and Classification by Machine Learning Algorithms
In this paper, a new supervised hierarchical clustering algorithm is proposed including a new metric that uses additional information available from the gene selection with the DPLS method. VIP values, representing the importance of the genes in the DPLS, can be considered as a good information source for increasing the clustering efficiency and interpretation capability of a clustering algorithm. It is reasonable to assume that the weights of the genes in the clustering are proportional to their importance in the determination of the class labels; that is, the higher the weight, the better the distinction power of the genes with respect to the class label.
A new weighted Euclidean distance (d ij (w) ) is proposed as a distance metric using the normalized VIP weights as follows:
where w = (w 1 , w 2 , ..., w k ) is the feature-weight vector with the normalized VIP values and N is the number of samples. Therefore, the normalized weights which are based on the VIP weights are assigned to each gene for indicating the importance of those genes (Questier et al., 2005) . Their weights are the importance degree corresponding to each feature. The larger w k (VIP k ) is, the more important the k-th gene is in the hierarchical clustering. When w is (1, ..., 1), the space {||d ij (w) || ≤ r} is a hypersphere with radius r in the well-known Euclidean space (called the original space). In the original space, d ij (w) is then denoted by d ij and the supervised hierarchical clustering would reduce to an unsupervised hierarchical clustering algorithm. When w ≠ (1, ..., 1), it means that the axes of the hypersphere would be extended or shrunk in accordance with the value of w k . Thus in this case the space {||d ij (w) || ≤ r} is a hyper-ellipse, and the lower the value of w k is, the higher the flattening extent of the ellipse is for that dimension. It is well known that an appropriate assignment of feature-weights can improve the performance of feature-weighted (supervised) hierarchical clustering algorithms (Wang et al., 2004) . This weighted distance can be easily proven to satisfy four requirements of a generic metric: nonnegativity, reflectivity, symmetry and triangle inequality.
According to Johnson and Wichern (1992) , the following are the steps in the suggested agglomerative supervised hierarchical clustering algorithm for a group of N samples. 1. Start with N clusters, each contains a single entity and an N × N symmetric matrix of the weighted distance D = {d ij (w) }. 2. Search the weighted distance matrix for the nearest (most similar) pair of clusters. Let the distance between the "most similar" clusters U and V be d UV . 3. Merge cluster U and V. Label the newly formed cluster (U V). Update the entries in the distance matrix by (a) deleting the rows and columns corresponding to clusters U and V and (b) adding a row and column giving the distances between cluster (U V) and the remaining clusters. 4. Repeat steps 2 and 3 a total of (N -1) times.
Record the identity of clusters that are merged and the levels at which the mergers take place. Figure 1 shows a schematic diagram of the supervised gene selection, clustering and classification by supervised machine learning algorithms for discriminating cancer subclasses. First, the key genes are selected using the VIP information of the DPLS model. Secondly, a weighted Euclidean distance is calculated for the proposed supervised clustering using the VIP weights. Thirdly, multivariate analysis and supervised clustering for cancer subclasses are used to interpret gene expression patterns, to classify the sample into a subclass, or to predict the clinical results of treatment. Because the proposed method makes use of the DPLS method in both supervised gene selection and supervised clustering, we expect to obtain synergistic effects of the supervised knowledge that is responsible for selecting the key genes, by sequentially using the influence of the key genes into a supervised hierarchical clustering and classification method. Supervised machine learning algorithms are applied to three microarray data sets obtained from leukemia, breast, and colon cancer patients to establish a relationship between the microarray data and expression-based cancer subclasses as well as patient treatment outcome.
Results and Discussion
Leukemia gene expression profiles
Leukemia is a malignant cancer that originates in cells in the bone marrow, and is characterized by uncontrolled growth of developing white blood cells. The bone marrow normally generates cells called blasts that develop (mature) into several different types of blood cells with specific tasks in the human body. Acute leukemia data set can be classified into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Moreover, ALL cases can be classified into T-cell ALL and B-cell ALL, depending on the type of lymphocytes that is affected (Golub et al., 1999) . Medical treatment of patients will vary depending on the leukemia class. Thus, knowledge of the leukemia class is very important information for doctors to correctly treat patients.
The leukemia data set and all details with respect to the methods used to collect the data are described in the paper of Golub et al. (1999) . The data set consists of a set of high-density oligonucleotide microarrays (Affymetrix) with probes of 7129 human genes, and was obtained from 72 patients. 47 patients were affected with ALL (38 B-ALL and 9 T-ALL), and 25 patients were affected with AML. The training data set consists of 38 bone marrow samples: 27 samples were taken from ALL patients (19 B-ALL and 8 T-ALL) and 11 were taken from AML patients. (Golub et al., 1999) (test) data set consisted of 34 samples: 20 ALL patients and 14 AML patients. Furthermore, a description of cancer subtypes, treatment response, patient gender, and laboratory that performed the analysis is provided with the data (Golub et al., 1999) . Table 1 provides some information on the leukemia subclasses to which each of the leukemia microarray data sets belongs. Moreover, the result of the subsequent medical treatment (success or failure) is provided for a limited number of samples. The gene expression profiles of the original data set are represented as log10 normalized expression values, such that overall intensities for each chip are equivalent. To remove systematic sources of variation in the microarray experiments, the expression level of each gene was normalized to have a zero mean and a standard deviation of one (Yang et al., 2002) . The proposed method is applied to the acute leukemia data set published by Golub et al. (1999) for four different cases: (1) discrimination between acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), (2) ALL subtype prediction (T-cell or B-cell), (3) AML subtype prediction (M1, M2, M4, or M5), and (4) AML subtype clinical outcome prediction (success or failure).
Supervised clustering of leukemia data set 3.2.1 Supervised clustering between ALL and AML
The DPLS method was used for selection of the genes that are most suited to discriminate between AML and ALL in the training data set of Golub et al. (1999) , where the response variable Y was either 0 (AML) or 1 (ALL). Out of the 7129 available genes in the expression data, the 23 genes which are most correlated with the leukemia classification into ALL or AML were selected on the basis of the VIP value resulting from applying DPLS. The cross validation method was used to determine the number of relevant genes to be retained. This method reconstructs a DPLS model with a minimal number of genes until the classification performance of DPLS in a cross validation does not decrease. This procedure finally resulted in the selection of 23 genes as the minimum number of genes that provides a good classification performance. In contrast to Golub et al. (1999) , who selected 50 relevant genes, the approach used here results in the selection of a significantly lower number of relevant genes. The DPLSbased gene selection method assigns high rankings to zyxin, leukotriene (C4 synthase gene), leptin, CD33 antigen, FAH, as well as cystatins and cathepsins. These genes are known to play important roles in acute leukemia. For example, zyxin is located in chromosome 7, which may contain genes related to myeloid malignancy, and cystatins are endogenous protein inhibitors of cathepsins, and hence these specific protease inhibitors might be important in the etiology of ALL and AML (Cho et al., 2002) . In addition, CD33 is located in chromosome 19q13.3, and has been developed for targeted antibody therapy to kill leukemia AML cells (Golub et al., 1999; Thomas et al., 2001; Bicciato et al., 2002; Cho et al., 2002) .
Figure 2(a) shows gene expression maps of a leukemia data set based on the 23 selected genes most relevant for discrimination between ALL and AML, where we used CLUSTER and TREEVIEW software, which are both publicly available at http://rana.lbl.gov. The figure confirms that the expression of the selected genes is significantly different for ALL and AML samples, and that expression of the individual genes is rather similar within each class. From this figure, we can conclude that the genes selected via VIP are discriminatory.
Supervised hierarchical clustering with the agglomerative linkage algorithm was applied to the 38 Fig. 2 Gene expression heat maps of a leukemia data set based on (a) the 23 selected genes most relevant for discrimination between ALL and AML and (b) the 21 selected genes most relevant for discrimination between success and failure of AML leukemia treatment samples of the training data set, in order to cluster the samples on the basis of their weighted similarities over the selected 23 genes. In the dendrogram (Figure 3(a) ), two clusters appear, corresponding to ALL and AML respectively. There is no discrimination error for the supervised clustering. On the other hand, when no information on the relative importance of each gene for leukemia class distinction was used in the clustering, the unsupervised clustering analysis shows a single misclustered sample (sample 35), which is AML but was clustered as ALL. This confirms that the supervised (weighted) hierarchical clustering analysis can improve the clustering performance for discriminating ALL and AML subclasses, since the normalized weights of the VIP can give relative contribution values to each gene for discrimination of subclasses. 3.2.2 Supervised clustering for ALL subclass (B-cell and T-cell) ALL can be further classified into Tcell and B-cell lineages. In clinical practice, the B-cell lineage responds better to treatment than the T-cell lineage. Therefore, it is important to distinguish between these lineages. Among the 47 ALL patients of Golub et al. (1999) , 27 patients were used as a training data set (19 B-cell ALL and 8 T-cell ALL). The DPLS method combined with the cross validation method resulted in the selection of 15 genes that allow discriminating between T-cell ALL (T-ALL) and B-cell ALL (B-ALL). The DPLS response variable Y is 0 (T-ALL) or 1 (B-ALL). The 15 genes were examined for chromosomal localization using NCBI LocusLink (http:// www.ncbi.nlm.nih.gov/LocusLink). Almost all genes are mapped to regions that have been previously associated with ALL chromosomal abnormalities, including the T-cell antigen receptor (X03934, 9p56), TCRB (X00437, 7q34) (CD47, X69398 3q13), CD7 (D00749, 7q34) and TCF7(X59871, 5q31). The results thus suggest that the 15 genes selected via DPLS as being most relevant for discriminating between B-ALL and T-ALL subclasses are biologically relevant as well. The subsequent supervised hierarchical clustering for the training data set using the expression information of the 15 selected genes resulted in correct clustering for all samples, confirming that the selected genes can be used to discriminate B-ALL and T-ALL subclasses.
Supervised clustering between AML subclasses
The original French-American-British (FAB) system for detemining leukemia subtype was only based on the appearance of leukemic cells under the microscope after routine processing or cytochemical staining. AML can be classified into six subtypes, designated M1, M2, M3, M4, M5, and M6. Although patients tend to be classified into either the M2 or M4 subtype under the FAB system, it is difficult for most doctors to discriminate sharply between these subtypes. Identifying the M3 subtype is of importance because this subtype usually responds well to treatment with retinoids. The M5 subtype is not easy to detect using the FAB system, and usually shows poor response to treatment. Most doctors recommend intensive chemotherapy for patients with this subtype. Clearly, correct identification of the AML subtype is very important to the subsequent clinical treatment step (Golub et al.,1999) .
Among the 25 AML patients, data of 20 patients were used as a training data set, (4 M1 cases: samples 32, 35, 38, 61; 10 M2 cases: samples 28, 29, 33, 34, 37, 51, 53, 57, 58, 60; for which monoclonal antibodies have been demonstrated to be useful in distinguishing lymphoid from myeloid lineage cells (Dorrie et al., 2001) .
Unsupervised and supervised clustering were applied to the training data set for the 25 selected genes most relevant for discrimination between AML subclasses (M1, M2, M4 and M5). For both clustering methods, there is one misclustered sample: Sample 51 is M2 but was clustered as M1. 3.2.4 Supervised clustering for clinical outcome of AML patients (failure and success)
Relating gene expression patterns to the clinical outcome of cancer treatment is a key issue in cancer genetics. One of the most promising aspects of gene expression profiling is the hope that it will enable more accurate identification of patients who are at a high risk of failing conventional therapy. Gene selection for the prediction of the clinical output of AML treatment (success or failure) was performed using DPLS. Among the 25 AML patients of Golub et al. (1999) with know clinical outcome of leukemia treatment, 15 samples formed a training data set (7 patients survived: 34-38 and 52-53; 8 patients died during treatment: 28-33, 50 and 51 (see Table 1 ). The response variable Y was 0 (success) or 1 (failure).
A subset of 21 genes was selected for discriminating between failure and success of clinical treatment of AML patients, as a result of applying DPLS with the crossvalidation method. The chromosomal locations of the 21 identified genes were checked in the NCBI, because chromosomal abnormalities are prevalent in leukemia patients and often have prognostic implications (Thomas et al., 2001) . Almost all genes among the selected 21 genes have been identified previously as containing abnormalities in AML or another form of leukemia. Most of the genes reported by Lyons-Weiler et al. (2003) are also found in our DPLS gene set (HoxA9, PIG-B, MACH-alpha-2 protein, BPI Bactericidal/permeability increasing protein, Autoantigen PM-SCL, ERGIC-53 Protein, and so on). Figure 2(b) shows a heat map of the leukemia gene expression data based on the 21 selected genes most relevant for discrimination between success and failure of AML leukemia treatment. It illustrates that the selected genes have a significant expression difference for AML leukemia treatment success and failure. The figure thus indicates that the selected genes can be used as a set of diagnostic genes for discrimination between the treatment results of AML patients. Figure 3(b) shows the dendrogram resulting from applying the supervised hierarchical clustering analysis to the training data set using the selected 21 genes. This clustering analysis divides the treatment failure and success in two distinct groups, which perfectly match with the recorded treatment results. The location of all successful treatments and all treatment failures in two separate groups indicates that the candidate genes selected via VIP can be used successfully as a set of diagnostic genes for discrimination between the treatment results of AML patients. Similarly to previous cases, the clustering appears to be improved by inclusion of VIP weights.
The gene selection indicated that HoxA9 was the most relevant gene for discriminating between successful and failing leukemia treatment. Overexpression of HoxA9 would presumably result in an overproduction of leukocytes and lymphocytes. Indeed, the injection of retrovirally engineered primary bone marrow cells that overexpressed both HoxA9 and Meis1 into mice induces AML within three months (Kroon et al., 1998) . Golub et al. (1999) found that HoxA9 had the highest correlation to their ideal distribution, but did not find a suitable gene set that enabled predicting chemotherapy success and failure. Thomas et al. (2001) suspected that, out of all the genes in the original data, HoxA9 could predict success and failure of chemotherapy, but were confronted with a lack of statistical significance in their measure of the difference between success and failure (P < 0.1). Figure 4 shows the gene expression profiles of HoxA9 in the 15 AML patients with known clinical outcomes (success = S; failure = F), where S means the patient survived after the treatment and F means the patient died after the treatment.
Among these patients, those with poor treatment outcomes showed increased expression of HoxA9. Biotechnological advances, such as gene expression profiling via DNA microarrays, allow researchers to enlarge their understanding of the mechanisms underlying diseases. The DNA microarray technology is useful when applied to RNA extracted from tissue samples: The resulting data allow discriminating between various subtypes of leukemia, which is necessary for the accurate diagnosis and treatment of patients. From the results demonstrated in this paper, we can conclude that the gene selection method via VIP can be used to select key genes for discriminating leukemia types and subtypes. The method also allowed successful prediction of medical outcome of leukemia treatment using gene expression data. Moreover the supervised clustering can improve the clustering performance for discriminating leukemia subclasses, compared to unsupervised clustering.
Supervised Classifications by Machine Learning
With the information on the most relevant features in a gene expression data set available, a following step is to build a robust cancer classifier capable of correctly predicting the sample labels from the available expression profiles. Supervised machine learning techniques are well-suited for this purpose. Two feature selection methods are compared: PCA as an unsupervised feature selection method and FLD as a supervised feature selection method. Two supervised classification methods, LDF and nonlinear SVM are subsequently applied to classify leukemia gene expression samples. This paper focuses on two case studies: Classification of samples into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) on the one hand, and classification of clinical treatment outcomes for AML patients (treatment success or failure) on the other hand. These two case studies are selected since they are considered to be more important for the classification of leukemia patients than the other case studies considered in the first part of this paper. applied to obtain a further dimension reduction of the 23 most relevant genes retained by Yoo et al. (2005) in order to interpret and avoid overfitting problems, since the gene expression data are too related to the response value. LDF was subsequently applied as a classifier. The dimension reduction obtained with PCA allowed to visualize the patterns of ALL and AML in the leukemia data set, and to improve the classification performance. Indeed, two PCs which capture about 74.3% of the variation in the 23 genes were found to be adequate based on the cross-validation of the prediction residual sum of squares (PRESS). The LDF classification results for AML and ALL samples are provided in Figure 5 . Figure 5(a) illustrates the classification result of the LDF for the training data set (38 samples), where ALL and AML samples are well separated. Figure 5(b) shows the classification results of 34 test patients in the two-dimensional space formed by the first two PCs. The test data set was classified with 97% accuracy (33/34 patients) using LDF. The only misclassified sample corresponds to patient 66, which was classified as ALL but actually labeled AML. Reclassifying the samples using the original 23 genes selected in the first paper, also showed one misclassification result for sample 66 using LDF. Several investigations indicated that the leukemia data set of Golub et al. (1999) contains at least one sample including patient 66 that is mislabeled and patient 66 has unusually low gene expression levels compared to other AML patients. Yoo et al. (2005) showed that the contributions of most genes in the 66th patient are negative, contrary to the behavior of the other AML patients. In particular, the top-ranked gene, Zyxin, shows an abnormally low expression level for patient 66. It means that there is actually no classification error for the 34 test data since sample number #66 is known as the mislabeled sample in the leukemia data set. Thus, it can be concluded that a further dimension reduction by PCA enables extraction of meaningful features that permit distinguishing between ALL and AML. This classification result is superior to that of Golub et al. (1999) , who obtained a total of five misclassifications from applying a weighted voting scheme, a variation of a diagonal linear classifier. The result is also better than that of Liang and Kachalo (2002) , who achieved three classification errors by a linear classifier.
In developing a nonlinear classifier like SVM, the most important thing is the extraction of appropriate features, that is which features are retained from the original inputs, in order to avoid the overfitting problem (Schölkopf et al., 2000) . In order to see the effect of the feature extraction on the classifier performance, four different classifiers were used on the data: Linear and nonlinear SVM were applied to the original gene data (23 genes), selected by Yoo et al. (2005) and to two reduced scores resulting from applying FLD to the original data. Each classifier uses the SVM algorithm to define a hyperplane that best separates the training samples into two classes, ALL and AML. In this paper, the radial basis function exp(-||x -y|| 2 /c) is used as a SVM kernel function to capture the nonlinearity. The width of a Gaussian function c = 1.5µ is selected, as suggested by Cremers et al. (2003) , in order to get a smooth energy landscape, where µ is the average distance between two neighboring data points. Data normalization is used for kernels to improve the condition number of the Hessian in the optimization routine. The parameter C which places an upper bound on the Lagrange multipliers is set to 1 for implementing linear and nonlinear SVM, and for reducing the number of support vectors. Table 2 shows the classification performance of the four classifiers for identifying ALL and AML labels. Linear and nonlinear SVM have very similar classification results for distinguishing between ALL and AML, both for the original features and the FLD scores. The training samples are perfectly classified, except for method 2, the nonlinear SVM applied to the original features. The classification performance evaluation for the test samples shows 1 to 2 errors for all four classifiers on a total of 34 test samples. Compared to the other methods, the result of method 1 (linear SVM applied to the original features) was not good, with 2 misclassified test samples. It indicates that the original data (23 genes) may contain non-separable signals or be corrupted by a high noise. Note also that the number of support vectors for method 2 is 35 while only 38 training samples were used. This means that the original 23 genes may contain a lot of noise and can easily be overfitted. A high number of support vectors for a data set forms indeed an indication that the SVM model may be overfitted, and that significant misclassification rates can be expected for the training and test samples. The classification results of methods 3 and 4, which are the linear and nonlinear SVM applied to two FLD score vectors, are quite similar. Sample 66 is misclassified with 2 support vectors. The features extracted via FLD make it a simple model, in which the number of support vectors for the classifier decreases to only two. In spite of this small number of support vectors, the classification results for both the training and test samples are good. Note that sample number #66 is known as the mislabeled sample in the leukemia data set. It means there is no classification error of SVM for the test data except the mislabeled sample #66. This demonstrates the fact that a dimension reduction (i.e. feature extraction) by FLD can improve the generalization performance of a classifier such as SVM.
To further evaluate the performance of the proposed method, we compared our method with previously developed methods which were applied to the same leukemia microarray data set. In general, it is somewhat difficult to directly compare these methods because they each use a different criterion. We compared their classification performance using the number of the misclassification samples. Table 3 compares the misclassification results of 34 test set using some previously published results, such as decision tree learner J48 (Weka's implementation of C4.5), simple Bayesian classifier or naive Bayes, sequential minimal optimization(SMO)-wrapper, emerging patterns (Li and Wong, 2002) , SVM (Fuery et al., 2000) , voting machine (Golub et al., 1999) , maximal margin linear programming (MAMA, Antonov et al., 2004) , and projective adaptive resonance theory (PART, . As one of the most well-known results, the previous result of the voting machine with 50 genes by Golub et al. (1999) can correctly predict 29 samples in the test set with 4 misclassified samples. The proposed method can correctly predict the test samples with a relatively low number of selected genes (23) except for a single misclassified sample (#66), which is known as a mislabeled sample and may influence the error rate (Chow et al., 2001) . The comparison of the method proposed in this paper with previously published results thus demonstrates that classification performance of the proposed method is equivalent or better than results reported in the literature. 3.3.2 Classification of clinical outcome of AML patient treatment (success or failure)
The FAB system for classifying AML subtypes was originally only based on the morphological states of cells under the microscope, and has later on been extended with criteria based on immune markers and cytogenetic abnormalities. Correct determination of the AML subtype is important, since different subtypes will respond differently to medical treatment. Gene expression data also contain information that can elucidate the success or failure of leukemia treatment. Designing a suitable classifier thus allows predicting the clinical outcome of leukemia patient treatment. The 21 most relevant genes for discriminating between failure and success of clinical treatment of AML patients selected in the first part of this paper were used as a starting point for the development of a classifier. PCA was used to reduce the data dimensionality, and to interpret the clinical outcome of AML patient treatment. Two PCs were used, which captured about 63.6% of the variation in the 21 genes.
The score and loading plots of the 15 AML patients included in the training set (8 failures and 7 successes) were examined for determining the correlation between the selected genes and the clinical outcome of AML patient treatment (Figure 6) . The plots clearly demonstrate that the selected 21 genes can exactly discriminate the clinical outcome of AML patients, and that PCA can extract the key feature components. The loadings plot in Figure 6 (b) can be used to establish how the 21 genes are interrelated. The shape of the loading plot is closely connected with the pattern of the score plot in Figure 6 (a), and shows how the 21 genes are expressed, and how they interact to separate the AML patients based on clinical outcome. In the loading plot, genes that correlate with successful treatment appear on the right hand side and genes that correlate with treatment failure appear on the left hand side. Almost all of the genes in each gene group have common expression patterns, that is, group-specific regulation patterns known as co-regulation patterns. It means that the expression of each group is highly elevated only in one sample class, and down-regulated in the other classes . This result is notable in that these genes may be considered marker genes related to the clinical outcome of AML patient treatment. Figure 7 shows the classification results obtained by combining PCA and LDF for all 25 AML patients, including the 15 training samples (8 treatment failures, 7 successes), and 10 test samples (patient 54, 57, 58, 60-66) . Samples are plotted in the space spanned by the first two PCs. Figure 7 (a), after applying the linear classifier in the two PC space, illustrates that the information contained in the 21 genes provides excellent separation for the 15 training sample AML patients with respect to the clinical outcome of the treatment. Figure 7 (b) depicts the classification results of PCA and LDF for the 10 AML patients in the test data set (54, 57, 58, (60) (61) (62) (63) (64) (65) (66) , whose clinical outcome was not specified by Golub et al. (1999) . The classification results point towards successful treatment for eight AML patients (#54, 57, 58, 62, 63, 64, 65, and 66) . Two AML patients (#61 and 62) are predicted not to survive treatment. Thus, the classifier is able to predict the clinical outcome of AML patients, but the performance of the classifier on the test samples cannot be evaluated since the appropriate information on patient survival is not available. Table 4 represents the prediction results of several SVM classifiers for the 10 AML patients of the test data set, whose clinical outcome was not specified by Golub et al. (1999) . All classifiers, linear as well as nonlinear classifiers, both applied on the original gene expression data (21 genes) as well as on two FLD score vectors, showed exactly the same clinical outcome prediction of AML patients. Eight AML patients (samples 54, 57, 58, 62, 63, 64, 65, and 66 ) are predicted to survive after treatment, and two AML patients (#61 and 62) are predicted to die after treatment. Thus, the conclusion is that a dimension reduction by FLD enables extracting the meaningful features to discriminate between success and failure of AML treatment. Based on the present findings with regard to the link between expression of certain genes and clinical outcome of AML treatment, determining the specific genes combined with the proposed classifiers would allow predicting relapse in leukemia patients. Although clinical outcome is also affected by many other factors, such as patient age, treatment regime, and time of diagnosis, the results presented here highlight the potential of the proposed method for uncovering prognostic indicators for leukemia.
Supervised classification of breast and colon cancer data sets
To evaluate the performance of the proposed supervised classification method, two additional data sets are selected-a breast cancer microarray data set and a colon cancer microarray data set-and the proposed method is compared with three previously developed methods. The breast cancer data set is used for the discrimination between BRCA1 mutation, BRCA2 mutation and other mutations (data set consisting of seven BRCA1 mutation samples and eight BRCA2 mutation samples and sporadic samples) with 3226 genes and 22 samples (Hedenfalk et al., 2001) . The colon cancer data set is used for diagnosis of cancer patients and consists of 2000 probes and 62 samples (40 cancer tissues and 22 normal tissues, Alon et al., 1999) . Although it is somewhat difficult to compare these methods because they each use a different criterion, the number of misclassifications is used for the comparison. Table 5 shows the comparison results with Bayesian variable selection , kernel Fisher discriminant analysis (FDA, Li et al., 2002; Cho et al., 2003 Cho et al., , 2004 . The gene set that was selected by Cho et al. (2004) is used in this paper.
For the breast cancer data set, the proposed method shows a satisfactory classification result in Table 5 . While Cho et al. (2003) produced 3 misclassification samples over three models, the results of our method and results reported by Lee et al. (2003) and Cho et al. (2004) Cho et al. (2004) the approach of Lee et al. (2003) is based on a quite complex method which is composed of Bayesian mixtures and markov chain monte carlo computation. From this result, we can conclude that the proposed method performs well and is much simpler and thus easier to use than the methods of Lee et al. (2003) and Cho et al. (2003 Cho et al. ( , 2004 . For the colon cancer data set, previously analyzed it using the average performance over 100 random partitions into 50 training and 12 test samples. As shown in Table 5 , the proposed methodreaching classification using a limited set of informative genes which are specific to a certain type of cancer-shows a minimum average test error that is lower than the error reported by . The selected genes in the colon cancer data set used for classification with the proposed method contain the vascular endothelial growth factor (VEGF, IMAGE ID:47326). The clinical studies show that VEGF is a dominant angiogenic factor in human colorectal cancer and is associated with the formation of metastases and poor prognosis (Cho et al., 2004) .
These results lead to the following conclusion. First, the classification result which can exactly classify the tumor type is mainly dependent on the selected genes. Research by Dettling and Buhlmann (2002) also shows that a supervised clustering algorithm can identify functional groups of interacting genes that have high explanatory power for the given tumor type, which in turn can be used to accurately predict the class labels of new samples. Second, as noted by Kulkarni et al. (2005) , supervised clustering with DPLS information of the tumor types of the tissues makes local transformations with supervised translations in the gene expression data. It changes the representation of the data whose class overlap is decreased slightly as compared to their original data distribution.
Conclusions
In this paper, we develop a supervised framework for the gene selection, clustering, and classification of microarray gene expression profiles, thus allowing discrimination between cancer subclasses. First, the marker genes which have great classification ability for given cancer types are selected. Second, supervised clustering using the valuable weights information of DPLS was suggested to subsequently group the tumor samples into different classes, where the normalized weights of VIP can give relative contribution values for the discrimination of subclasses. Third, supervised linear and nonlinear classification methods were applied to three microarray data sets of (leukemia, breast, and colon cancer) to predict and classify the tumor samples according to their membership to particular tumor classes. Supervised machine learning algorithms enable the classification of leukemia subtypes solely on the basis of molecular-level monitoring. The performance of the proposed method, using only a limited set of informative genes, is demonstrated to be comparable or better than results reported in the literature. Furthermore, the use of the proposed method for predicting patient treatment outcome was demonstrated on the microarray data sets. Thus, the proposed methods can potentially be used to guide the design of new, more effective approaches for cancer treatment. 
